The rise of biologics, Advanced Therapy Medicinal Products (ATMPs), cell and gene therapies, and other highly specialized medicinal products has transformed quality control testing requirements across the pharmaceutical industry. Unlike traditional small-molecule drugs, these products are often produced in lower volumes, involve shorter manufacturing campaigns, and may have limited opportunities for reprocessing if contamination is detected.
As a result, sterility testing is a critical component of the overall Contamination Control Strategy (CCS), helping manufacturers ensure product sterility while minimizing risks to valuable product batches.
Regulatory guidance, including EU GMP Annex 1, increasingly emphasizes contamination prevention through Quality Risk Management principles, promoting technologies that reduce operator intervention and improve process consistency. In this evolving regulatory landscape, isolator technology has emerged as a preferred approach for many aseptic applications, including sterility testing.
The Bioquell QubeTM isolator provides a flexible, self-contained aseptic processing environment designed to support sterility testing, mycoplasma testing, cell culture activities, and other contamination-sensitive workflows while reducing reliance on traditional cleanroom infrastructure.
Sterility Testing Challenges in Modern Biopharmaceutical Manufacturing
Sterility testing laboratories supporting ATMPs and biologics face challenges that differ significantly from those encountered with conventional pharmaceutical products. Many therapies are produced in small batch sizes, patient-specific or autologous, highly sensitive to environmental contamination, time critical, and associated with significant clinical consequences if a batch fails.
In these environments, maintaining aseptic conditions throughout the testing process is essential. Even a single contamination event may trigger complex investigations, delay product release, or potentially lead to batch rejection.
Annex 1 emphasizes that contamination control should be managed through a comprehensive Contamination Control Strategy (CCS) incorporating facility, equipment, process, personnel, and monitoring controls (EU GMP Annex 1, Principle and Section 2). The guidance further states: "Restricted Access Barrier Systems (RABS) or isolators are beneficial in assuring required conditions and minimizing microbial contamination associated with direct human interventions in the critical zone. Their use should be considered in the CCS" (EU GMP Annex 1, Section 4.3). Consequently, barrier technologies such as isolators are increasingly being utilized to help reduce contamination risk and support sterility assurance programs.
Rather than relying solely on room classification and operator gowning practices, isolators create a physical barrier between the product and personnel, providing a higher level of environmental control.
Why Isolators Are Becoming the Preferred Sterility Testing Environment
Traditional sterility testing suites often depend on classified cleanroom environments and biological safety cabinets to maintain aseptic conditions. While effective, these systems can remain vulnerable to contamination originating from operators, materials, or environmental disturbances.
Barrier technology changes the contamination control model by physically separating the testing environment from the surrounding room and personnel.
This approach aligns closely with Annex 1's focus on reducing contamination risks at their source through engineering controls rather than relying exclusively on procedural controls.
By isolating critical manipulations from the external environment, laboratories can help reduce operator-related contamination risks and help improve repeatability. Another benefit comes by maintaining controlled conditions independent of room activity
For organizations processing diverse biologics or supporting multiple clients, these advantages become increasingly important as testing demand grows.
Bioquell Qube Isolator: Engineering Aseptic Assurance into the Workflow
The Bioquell Qube isolator extends the advantages of traditional isolator technology by combining aseptic processing capabilities with integrated hydrogen peroxide vapor bio-decontamination.
Rather than relying on manual cleaning alone, the system can perform validated automated bio-decontamination cycles that prepare the internal environment before testing activities begin.
This capability helps establish a reproducible starting condition for each test session and supports contamination control objectives outlined within a facility's overall CCS.
Key features that support sterility testing operations include:
Integrated Automated Bio-Decontamination
The Bioquell Qube isolator utilizes automated hydrogen peroxide vapor bio-decontamination designed to achieve consistent results on exposed internal surfaces. This helps reduce variability that can occur with manual preparation methods while supporting validation programs that require documented and repeatable decontamination performance.
For sterility testing laboratories, this allows standardized chamber preparation. Working in this enclosed environment allows for a reduced dependence on operator technique, although still a core emphasis, and can help deliver improved reproducibility between testing campaigns. The system also provides documented cycle records and the capability for audit trail software.
Material Transfer Without Disrupting Operations
Material transfer remains one of the most significant contamination risks in aseptic processing environments.
Bioquell Qube systems can be configured to support specific workflows and laboratory layouts. This flexibility is particularly valuable in ATMP laboratories where testing demand can evolve rapidly as products move from clinical development to commercialization. Users can separate activities between chambers and bring in decontaminated supplies without interrupting their current workflow.
The Bioquell Qube isolator allows materials to be introduced through dedicated transfer ports that maintain containment and environmental control.
In many workflows, materials can undergo independent bio-decontamination prior to entry into the primary workspace. This allows testing activities to continue without requiring full chamber reconditioning, helping reduce downtime and improve laboratory utilization.
Support for Sterility Test Equipment Integration
Sterility testing often requires integration of pumps, filtration systems, incubation equipment, and sample handling systems.
The Bioquell Qube isolator can be configured to accommodate supporting equipment while maintaining a controlled environment, helping laboratories optimize workflows without compromising aseptic assurance.
Supporting Regulatory Expectations for Sterility Assurance
Regulators increasingly expect contamination control measures to be proactive, science-based, and justified through risk management principles.
Annex 1 emphasizes: Quality Risk Management (QRM); contamination control strategies (CCS); reduction of interventions; closed and barrier-based technologies; demonstrated process control; and effective environmental monitoring
The use of isolators directly supports many of these objectives by reducing the reliance on personnel practices as the primary contamination control mechanism.
Data Integrity and Traceability
Testing environments increasingly require detailed documentation and traceability. Monitoring and cycle documentation can support audit readiness, investigation activities, validation requirements, trending analyses, and data integrity initiatives. When integrated into validated quality systems, this documentation can help support compliance expectations related to data management and electronic recordkeeping.
Scaling Sterility Testing Capacity for Growing ATMP Pipelines
As cell and gene therapy pipelines continue to expand, testing laboratories face increasing pressure to perform more sterility tests while maintaining consistency and regulatory compliance. Unlike traditional large-scale commercial manufacturing, Advanced Therapy Medicinal Product (ATMP) programs often manage multiple products simultaneously, accommodate variable batch sizes, adapt to frequent process changes, and support short production campaigns while preparing for rapid growth. These dynamic operating conditions can challenge fixed testing infrastructures.
The scalable design of the Bioquell Qube provides laboratories with the ability to increase processing capacity incrementally while maintaining standardized operating conditions. This approach allows organizations to expand testing capabilities in alignment with business growth rather than committing to large facility modifications before demand materializes.
Beyond Sterility Testing: Supporting Broader Contamination Control Strategies
While sterility testing represents a critical application, the value of isolator technology extends into broader contamination control programs.
Many organizations are adopting process-level contamination control approaches in which critical operations are protected through localized barrier systems rather than relying exclusively on facility-level controls.
The Bioquell Qube isolator can support multiple contamination-sensitive workflows, including:
- Sterility testing
- Cell processing activities
- Media preparation
- Mycoplasma testing workflows
- Research and development applications
- Method development and validation studies
This flexibility allows laboratories to utilize a common platform while adapting to evolving process requirements.
Conclusion: Building Sterility Assurance Around Process-Level Control
As biologics, ATMPs, and personalized medicines continue to reshape pharmaceutical manufacturing, sterility testing environments must evolve beyond traditional approaches.
Regulatory expectations increasingly emphasize contamination prevention through engineering controls, risk management, and validated barrier technologies. Organizations that continue to rely primarily on classified cleanrooms and procedural controls may face increasing challenges in delivering the flexibility, repeatability, and contamination control required by modern therapies.
The Bioquell Qube isolator addresses these challenges by combining physical separation, modular design, automated hydrogen peroxide vapor bio-decontamination, and scalable aseptic processing capabilities within a single platform. By supporting process-level contamination control, the system enables laboratories to align sterility testing operations with the realities of modern biologics manufacturing while maintaining the consistency, traceability, and regulatory confidence required in highly regulated environments.
